Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058149 · ClinicalTrials.gov registry record · Phase 3
Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00058149: Completed Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
NCT00058149 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00058149, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy such as gemcitabine and oxaliplatin use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. It is not yet known whether gemcitabine is more effective with or without oxaliplatin in treating pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without oxaliplatin in treating patients who have locally advanced or metastatic pancreatic cancer.
Interventions
- DRUG oxaliplatin
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-03 |
| Phase | Phase 3 |
What the finished NCT00058149 record still lists
NCT00058149 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which oxaliplatin is the first listed.
NCT00058149 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00058149 about?
NCT00058149 is a clinical study titled "Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy such as gemcitabine and oxaliplatin use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. It is not yet known whether gemcitabine is more effect...
What is the current status of trial NCT00058149?
This trial is currently completed. It is a Phase 3 study. The study started on 2003-03.
What interventions are being tested in trial NCT00058149?
The interventions under investigation include: oxaliplatin (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00058149?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia